The Europe lymphedema treatment market was valued at USD 335.74 million in 2025 and is projected to reach USD 617.70 million by 2033, growing at a CAGR of 9.10% from 2026 to 2033. The market is witnessing steady growth driven by the rising prevalence of cancer-related lymphedema, growing awareness regarding early diagnosis and management, and increasing adoption of advanced compression therapy and surgical treatment solutions across European healthcare systems.
𝐕𝐢𝐬𝐢𝐭 𝐮𝐬 𝐧𝐨𝐰 -
The growing number of breast cancer survivors, expanding elderly population, and increasing incidence of chronic venous disorders are significantly contributing to market demand. In addition, supportive government healthcare initiatives, improved reimbursement frameworks, and the presence of specialized lymphedema clinics are encouraging wider access to treatment services. Technological advancements in pneumatic compression devices, minimally invasive lymphatic surgeries, and personalized rehabilitation therapies are further supporting market expansion across hospitals, rehabilitation centers, and homecare settings in Europe.